{"id":"W2083269457","doi":"10.1016/s1873-9954(08)70010-7","title":"9 ASSESSMENT OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF CROHN'S DISEASE IN PATIENTS FOR WHOM INFLIXIMAB TREATMENT WAS NOT SUCCESSFUL: OPEN-LABEL INDUCTION PRELIMINARY RESULTS FROM THE WELCOME STUDY","year":2008,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis Supplements","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Certolizumab pegol; Infliximab; Medicine; Crohn's disease; Open label; Adalimumab; Disease; Internal medicine; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003303192,0.0002426913,0.0007362521,0.0001972907,0.0001656567,0.00005979468,0.0003622062,0.0000604632,0.00003406763],"category_scores_gemma":[0.0001030301,0.0001344099,0.0001131178,0.0002306205,0.0001645843,0.0002431898,0.0001099643,0.0001431348,2.988213e-7],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004507594,"about_ca_system_score_gemma":0.003114434,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01116201,"about_ca_topic_score_gemma":0.0009959815,"domain_scores_codex":[0.9966897,0.0003277883,0.001361498,0.000294239,0.0009727406,0.0003540523],"domain_scores_gemma":[0.9978486,0.0005436711,0.0006513731,0.000472981,0.0003274932,0.0001559225],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1671395,0.05947913,0.7310123,0.0001449672,0.0009971851,0.003310357,0.02332675,0.00004295289,0.00002009493,0.00004792267,0.001229767,0.013249],"study_design_scores_gemma":[0.1695863,0.01952386,0.8064343,0.0001896594,0.000254509,0.00006315162,0.002306907,0.0004111608,0.0001193119,0.00004869601,0.0009741803,0.00008793019],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.99324,0.0002154372,0.000003860421,0.001043633,0.0001286954,0.004437939,0.0008769229,0.000001750843,0.0000517465],"genre_scores_gemma":[0.9982143,0.0008898023,0.0001797881,0.00003298864,0.0001190694,0.0002990144,0.0001549052,0.00002006008,0.00009006217],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07542194,"threshold_uncertainty_score":0.999314,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06588458941485871,"score_gpt":0.3734134110423851,"score_spread":0.3075288216275264,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}